SCHEMBL1714050

SCHEMBL1714050

O=C1NC(=S)NC1=Cc1c[nH]c2ncc(N3CCOCC3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
MAPK1 P28482 7/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TNNI3 P19429 1/20 0.38
TNNT2 P45379 1/20 0.38
TNNC1 P63316 1/20 0.38
RAB9A P51151 2/20 0.36
POLB P06746 1/20 0.36
RECQL P46063 1/20 0.36
MAP4K1 Q92918 2/20 0.36
MET P08581 1/20 0.36
IL2 P60568 1/20 0.36
KLKB1 P03952 1/20 0.36
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714048 1.00 MAPT (0.48) MAPTALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL14221229 0.90 MEN1 (0.46) MAPTALDH1A1SMN1; SMN2MAPK1MEN1
SCHEMBL1713730 0.79 MAPK1 (0.45) ALDH1A1MAPK1MEN1KMT2APOLB
SCHEMBL1714495 0.78 MEN1 (0.42) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1714497 0.78 MEN1 (0.42) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1714096 0.77 APAF1 (0.42) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1714706 0.77 MEN1 (0.41) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL12460055 0.77 MEN1 (0.41) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1714704 0.77 MEN1 (0.41) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1714098 0.77 APAF1 (0.42) MAPTALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 US disclosed
EP-2094699-A2 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 Sanofi-Aventis (FR) 2009-09-02 EP disclosed
WO-2008046982-A2 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 MAPT 2432/4885ALDH1A1 4307/4885SMN1; SMN2 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.